Research programme: mRNA therapeutics - Silence Therapeutics
Latest Information Update: 28 May 2020
Price :
$50 *
At a glance
- Originator Silence Therapeutics
- Class RNA
- Mechanism of Action Protein synthesis modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 May 2020 No recent reports of development identified for research development in Unspecified in England
- 12 Apr 2016 Early research in Undefined indication in England (unspecified route)